MedTrace Logo

Senolytics to Improve Osteoporosis Therapy

NCT06018467 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-05-11

No results posted yet for this study

Summary

This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and antioxidant therapy on bone.

Conditions

  • Osteopenia, Osteoporosis
  • Age-related Bone Loss

Interventions

DRUG

Dasatinib 100 Mg Oral Tablet

Dasatinib tablets in blister packs of 10 tablets, from either: "Sandoz", "STADA Nordic", "Zentiva" or "Bristol-Myers Squibb"

DIETARY_SUPPLEMENT

Quercetin 1.250 mg (oral)

five 200mg Quercetin Phytosome capsules, from Thorne

DIETARY_SUPPLEMENT

Nicotinamide Riboside 1g (oral)

four 250mg Nicotinamide Riboside Capsules, from Elysium Health

Sponsors & Collaborators

  • Odense Patient Data Explorative Network

    collaborator OTHER

  • The Novo Nordisk Foundation Center for Basic Metabolic Research

    collaborator OTHER

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Moustapha Kassem, DMSc, PhD · Head of Research, Department of Endocrinology, Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-06
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06018467 on ClinicalTrials.gov